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Abstract
Introduction: There are still not enough data showing whether patients with
idiopathic hirsutism (IH) also have insulin resistance. The association between
polycystic ovary syndrome (PCOS) and insulin resistance is well documented in
the literature, but the Rotterdam Consensus has concluded that principally obese
women with PCOS should be screened for the metabolic syndrome. We intend-
ed to investigate the presence/absence of insulin resistance in non-obese
women with hirsutism.
Material and methods: Twenty-eight women with PCOS (14 non-obese and 
14 obese), 12 non-obese with IH, and 16 non-obese healthy women were includ-
ed in the study. The presence of insulin resistance was investigated by using
basal insulin levels and the homeostasis model assessment (HOMA) score in
the study group.
Results: Patients with obese and nonobese PCOS had significantly (p < 0.05)
higher basal insulin levels and HOMA scores than IH and control subjects. Insulin
levels and HOMA scores did not differ between obese and non-obese PCOS
patients. Patients with IH did not show any difference from the control group.
Conclusions: Insulin resistance exists in non-obese women with PCOS as well
as obese women with PCOS. The PCOS is associated with insulin resistance
independent of obesity. Insulin resistance should be assessed in all hirsute
women with PCOS regardless of their body mass index. More studies in larger
numbers of patients should be performed to investigate the role of insulin resist-
ance in women with IH. 
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Introduction
Hirsutism is characterized by excessive growth of terminal hair in the
androgen-sensitive skin regions. It may result from various causes includ-
ing polycystic ovary syndrome, non-classic adrenal hyperplasia, adrenal or
ovarian tumors, or it may be idiopathic. Idiopathic hirsutism (IH) is the
second most common cause of hirsutism, after polycystic ovary syndrome
[1]. Idiopathic hirsutism is defined as hirsutism associated with normal
ovulatory function and normal circulating serum androgen concentrations
[2]. In these patients mild forms of ovarian and adrenal functional hyper-
androgenism may be present [3]. Polycystic ovary syndrome (PCOS) is
characterized by chronic anovulation, obesity and hyperandrogenism. The
Rotterdam Consensus Conference [4] proposed that the syndrome can be
diagnosed after the exclusion of other disorders (non-classical adrenal
hyperplasia, Cushing’s syndrome, hyperprolactinaemia, hypothyroidism,
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virilizing adrenal or ovarian neoplasm), and the
determination that at least two of the following are
present: oligoovulation or anovulation, elevated lev-
els of circulating androgens and/or clinical hyper-
androgenism, and polycystic ovaries as defined by
ultrasonography. Moreover, the Rotterdam Con-
sensus has concluded that principally obese women
with PCOS should be evaluated for the metabolic
syndrome. It is well known that hyperandrogenism
and insulin resistance are now closely associated.
However, there are not enough data showing
whether patients with IH also have insulin resist-
ance. 
Our aim was to investigate the presence/absen  -
ce of insulin resistance and hyperinsulinaemia in
especially non-obese women presenting with hir-
sutism.
Material and methods
Four groups of subjects were recruited: 14 obese
(body mass index [BMI] > 27 kg/m2) women with
PCOS, 14 non-obese (BMI < 25 kg/m2) women with
PCOS, 12 non-obese women with IH, and 16 non-
obese controls. The study group comprised patients
who attended the dermatology outpatient clinic. All
patients were consulted by the Department of
Endocrinology. The control subjects were matched
for age and weight to the women with PCOS and IH.
Obesity was defined as BMI > 27 kg/m2. The
diagnosis of PCOS was performed according to the
Rotterdam 2003 criteria [4]. Rotterdam diagnostic
criteria are shown in Table I. Patients with PCOS ful-
filled all three Rotterdam criteria. The group with
PCOS had oligomenorrhoea, polycystic ovarian mor-
phology on ultrasonography and hyperandrogene-
mia estimated by laboratory measurements. Hyper-
androgenemia was defined as a serum free
testosterone level greater than 3.9 pg/ml (normal:
0.04-3.9 pg/ml). Oligomenorrhoea was defined as
bleeding at intervals of greater than 35 days. Amen-
orrhea was defined as absence of menstruation for
6 months or more. Transabdominal or transvaginal
ovary ultrasound was performed for all patients in
the early follicular phase (days 3-9 of the menstru-
al cycle). Ovaries were classified as polycystic based
on the presence of 12 or more follicles in each ovary
measuring 2-8 mm in diameter, and/or increased
ovarian volume (> 10 ml) [4]. Thyroid dysfunction,
hyperprolactinaemia, non-classic congenital adre-
nal hyperplasia, and adrenal/ovarian tumors were
excluded by appropriate tests and ultrasonography
of the ovaries and the adrenal glands. In the con-
firmed PCOS group, any patient with a 17α-hydroxy-
progesterone level of > 2 ng/ml (normal: 0.2-
2.6 ng/ml) was subjected to an adrenocorticotrop-
ic hormone stimulation test (250 μg IV, Synachten;
Ciba-Geigy, Basel, Switzerland) to rule out non-clas-
sic congenital adrenal hyperplasia. Hirsutism was
defined as Ferriman-Gallwey (FG) score > 8 [5]. The
diagnosis of IH was based on the presence of hir-
sutism, regular ovulatory menstrual cycles, and
a normal serum androgen profile including free
testosterone (normal: 0.04-3.9 pg/ml) and dehy-
droepiandrosterone sulfate (normal: 35-430 μg/dl).
All controls had a regular cycle and no clinical or
laboratory features of PCOS. There was no history
of diabetes mellitus in the study group. All partici-
pants had not used any medication or oral contra-
ceptives for the last three months. 
In the study group, blood sampling was done in
the early follicular phase of spontaneous or induced
(by medroxyprogesterone acetate 10 mg/day for 
7 days) menstrual cycles. After an overnight fast,
blood samples were collected around 8-10 a.m. to
measure serum levels of free testosterone (FT),
dehydroepiandrosterone sulfate (DHEAS), prolactin
(PRL), 17α-hydroxyprogesterone (17-OHP), fasting
plasma glucose and insulin. Serum levels of DHEAS
and PRL were measured by electrochemilumines-
cence immunoassays (Elecsys, Roche Diagnostic
Corporation, Germany). Serum levels of FT and 
17-OHP were measured by a radioimmunoassay kit
(DPC, CA, USA). Plasma glucose levels were deter-
mined by the glucose oxidase technique with a glu-
cose analyser (Dimension, Dade Behring, Germany).
Plasma insulin concentrations were measured by
an insulin radioimmunoassay kit (DPC, CA, USA);
normal range 0-30 μIU/ml; inter-assay CV < 5%;
intra-assay CV < 8.5%. Insulin resistance was cal-
culated with homeostasis model assessment of
insulin resistance (HOMA-IR), using the following
formula: fasting serum insulin (μU/ml) × fasting
plasma glucose mmol/l)/22.5 [6]. 
Statistical analysis
Data analysis was performed using the SPSS 
11 software (Chicago, IL, USA). The distribution of vari-
ables was tested for normality. The results are report-
1. Oligo- or anovulation 
2. Clinical and/or biochemical hyperandrogenism findings
3. With polycystic ovarian appearance with exclusion of other causes
The presence of at least two of three diagnostic criteria is essential
Table I. 2003 Consensus Conference diagnostic criteria
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ed as means ± SD, ranges (min-max), median values
and interquartile range (IQR). The results of women
with PCOS, obese and non-obese, were compared
using the Mann-Whitney U test. As continuous vari-
ables were without normal distribution, we used non-
parametric tests. The comparisons of the non-obese
groups were made by the Kruskal-Wallis test. Value
of p < 0.05 was regarded as statistically significant. 
Results
Non-obese patients (PCOS, IH) and non-obese
control subjects did not differ in mean age (22.6
±4.1, 26.2 ±7.7, and 28.0 ±6.5 years, respectively 
p > 0.05; range: 18-30 for non-obese PCOS, 18-40
for non-obese IH and 18-39 for control subjects) and
BMI (22.9 ±2.1, 22.6 ±2.7, and 21.6 ±2.3 kg/m2,
respectively p > 0.05) values. The Ferriman-Gallwey
score was significantly higher in both women with
PCOS and women with IH compared with controls
(16.7 ±10.2, 11.4 ±2.7, 4.3 ±1.2, respectively p < 0.05).
Fasting glucose levels were similar in all groups
and there were no statistically significant differ-
ences. However, patients with non-obese PCOS had
significantly higher basal insulin levels and HOMA
scores than patients with IH and control subjects
(p < 0.05). Insulin levels and HOMA scores in
patients with IH did not show any differences from
the control subjects (p > 0.05). Age, BMI, fasting
glucose, insulin, and HOMA values of the nonobese
study group are shown in Table II. The women with
non-obese PCOS had higher levels of insulin as well
as women with obese PCOS and HOMA values
were similar in both groups (p > 0.05). Age, BMI,
fasting glucose, insu  lin, and HOMA values of groups
of obese and non-obese with PCOS are shown in
Table III.
Discussion
Polycystic ovary syndrome and IH account for
most cases of hirsutism [1]. Not all hirsute patients
have evidence of detectable androgen excess or
endocrine imbalance, as in women with IH. The
association of carbohydrate metabolism abnor-
malities with androgen excess disorders, particu-
larly PCOS, is a well-defined entity. Recognition of
the relationship between PCOS and insulin excess
dates to 1980 [7, 8]. Insulin resistance and hyper-
insulinism are now recognized as important fea-
tures of PCOS, stimulating ovarian androgen secre-
tion and suppressing sex hormone-binding globulin
production [8, 9]. Insulin resistance and hyperin-
sulinaemia contribute to ovarian and adrenal
cytochrome P450c17α activity in women with PCOS.
Dysregulation of cytochrome P450c17α enzyme
causes the exaggerated secretion of adrenal and
ovarian androgens in these women [9, 10].
Obesity is encountered in 30-70% of PCOS-
affected women, and its presence significantly mod-
ifies both clinical and laboratory expression of the
syndrome. Obesity increases the risk of co-mor-
bidities associated with PCOS, such as impaired glu-
cose tolerance and type 2 diabetes mellitus, hyper-
lipidaemia and arterial hypertension [11]. Weight
loss is the first choice recommendation for the
Age [years]B MI [kg/m2] Insulin (0-30)  Glucose (70-110) HOMA
[μU/ml] [g/dl]
Non-obese PCOS (n = 14)
Mean ± SD 22.64 ±4.16 22.96 ±2.14 20.79 ±20.57 88.57 ±7.86 4.49 ±4.17
Median (IQR) 23 (3.63) 22.9 (1.78) 12.05 (8.94) 86.5 (6.88) 2.76 (2.22)
Min-max 18-30 20.0-26.66 4.0-77.8 75-99 0.85-14.41
Non-obese IH (n = 12)
Mean ± SD 26.25 ±7.70 22.64 ±2.73 9.27 ±5.17 85.17 ±9.13 1.96 ±1.19
Median (IQR) 25.0 (7.25) 22.78 (2.66) 8.2 (5.1) 85.5 (3.75) 1.8 (1.01)
Min-max 18-40 17.91-26.42 3.0-18.4 61-100 0.61-4.54
Non-obese control (n = 16)
Mean ± SD 28.0 ±6.51 21.60 ±2.38 8.78 ±2.13 81.63 ±10.12 1.77 ±0.49
Median (IQR) 29.0 (4.75) 21.89 (1.75) 9.1 (1.93) 85.0 (9.0) 1.79 (0.40)
Min-max 18-39 17.26-24.97 5.4-12.0 62-94 0.92-2.56
Kruskal-Wallis test
χ2 5.074 2.035 6.034 2.700 7.853
p 0.079 0.361 0.049* 0.259 0.020*
Table II. General features of the non-obese study group
*p < 0.05
Filiz Cebeci, Nahide Onsun, Meral MertArch Med Sci 2, April / 2012 345
Insulin resistance in women with hirsutism
treatment of clinical manifestations of PCOS, such
as menstrual cycle irregularities, infertility or hir-
sutism [11, 12].
Ehrmann et al. [13] showed that women with
PCOS have a substantially higher impaired glucose
tolerance and diabetes mellitus than age- and body
weight-matched healthy women. The Rotterdam
Consensus has concluded that principally obese
women with PCOS should be evaluated for the
metabolic syndrome. Obesity itself is usually accom-
panied by insulin resistance. Therefore, we intend-
ed to investigate the presence/absence of insulin
resistance in women with especially non-obese
PCOS and non-obese IH. In the present study, sig-
nificantly higher insulin levels and an insulin-resis-
tant state were found in obese and non-obese
women with PCOS. Studies on the relationship
between obesity and hyperinsulinism in PCOS have
yielded conflicting results. Chang et al. [14] and
Dunaif et al. [15, 16] have demonstrated a degree
of decreased insulin sensitivity in both obese and
non-obese women by different methods. But oth-
ers have not been able to find any degree of insulin
resistance in non-obese women with PCOS [17-19].
In a recent study, it was demonstrated that non-
obese women with PCOS have insulin resistance
[20]. In our study, non-obese women with PCOS had
significantly higher basal insulin levels and HOMA
scores than non-obese women with IH and con-
trols. However, there was no statistically significant
difference with regard to insulin levels and HOMA
scores between obese and non-obese women. On
the other hand, we did not find any differences
between obese women and non-obese women with
respect to insulin levels and HOMA scores. Insulin
levels were significantly higher in non-obese PCOS.
Our findings showed that insulin resistance devel-
ops independently from obesity in all hirsute
women with PCOS. More recently, some studies
have suggested that there may be a link between
insulin resistance and hirsutism rather than body
weight in women with PCOS [21, 22].
Insulin also seems to be one of the factors that
interact with androgen to regulate pilosebaceous
unit development [8]. The effect of insulin and the
IGF system have been investigated by an in vitro
study [23]. Some authors have shown that
insulin/IGF plays a role in stimulating hair follicle
growth acting together with androgens [24]. The
pathophysiology of IH is presumed to involve a pri-
mary increase in skin 5α-reductase activity and pos-
sibly an alteration in androgen receptor function [2].
In these patients there may be present mild forms
of ovarian and adrenal functional hyperandrogenism
[3]. In the light of this information, we investigated
whether this peripheral increased androgen activi-
ty is associated with insulin metabolism. In contrast,
there are not enough data showing whether
patients with IH also have insulin resistance. Pao-
letti et al. [25] suggested that peripheral activity of
androgens is related to hyperinsulinaemia and that
anti-androgen treatment improves hyperinsuli-
naemia. Unlühizarci et al. [26] found a higher preva-
lence (18.7%) of impaired glucose tolerance among
women with IH, and these authors also suggested
that IH is associated with insulin resistance. Recent-
ly, insulin resistance was shown in obese patients
with IH in another study [27]. In our study, the
insulin levels and insulin-resistant state of women
with non-obese IH and the non-obese control group
did not show any differences. This might have been
due to the small number of women with IH.
In conclusion, insulin resistance should be
assessed in all hirsute women with PCOS regard-
Age [years]B MI [kg/m2] Insulin (0-30)  Glucose (70-110) HOMA
[μU/ml] [g/dl]
Obese PCOS (n = 14)
Mean ± SD 24.36 ±5.99 30.86 ±2.3 20.72 ±1.55 90.29 ±8.19 4.71 ±3.99
Median (IQR) 23 (4.63) 30.11 (1.75) 17.2 (5.5) 90.5 (5.63) 3.68 (1.44)
Min-max 18-40 28.80-36.39 7.3-69 77-103 1.62-17.55
Non-obese PCOS (n = 14)
Mean ± SD 22.64 ±4.16 22.96 ±2.14 20.79 ±20.57 88.57 ±7.86 4.49 ±4.17
Median (IQR) 23 (3.63) 22.9 (1.78) 12.05 (8.94) 86.5 (6.88) 2.76 (2.22)
Min-max 18-30 20-26.66 4-7.8 75-99 0.85-14.41
Mann-Whitney U test
Z 0.487 4.521 0.851 0.621 0.965
p 0.626 0.0001* 0.395 0.534 0.335
Table III. General features of obese and non-obese groups with PCOS
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less of their body mass index. More studies in larg-
er numbers of patients should be performed to
investigate the role of insulin resistance in women
with IH.
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